文献速递其他结缔组织病

免疫抑制治疗与系统性硬化症轻度间质性肺病病程的关联

Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该回顾性队列研究基于加拿大硬皮病研究组注册库,纳入294例病程小于7年且未使用过环磷酰胺(CYC)或霉酚酸酯(MMF)的系统性硬化症相关间质性肺病(SSc-ILD)患者,其中116例基线用力肺活量(FVC)预测值>85%被定义为轻度ILD。结果显示基线使用CYC或MMF者一年后FVC较未使用者高8.49%(95%CI:0.01-16.98%),且两年内无临床意义进展,提示轻度ILD阶段存在保留肺功能的干预窗口。

要点

  • 轻度SSc-ILD患者基线使用CYC或MMF与一年后FVC较高相关,差异为8.49%。
  • 暴露组两年内无临床意义进展,未暴露组24.6%出现进展。
  • 结果提示轻度ILD阶段可能是保留肺功能的治疗窗口。

核心结论

  • 在真实世界环境中,基线使用CYC或MMF与轻度SSc-ILD患者更高的FVC值和更低的进展风险相关。

研究设计与样本

  • 回顾性队列研究,从加拿大硬皮病研究组注册库构建,纳入294例病程小于7年且基线前未使用CYC或MMF的SSc-ILD患者。
  • 其中116例基线FVC预测值>85%被归类为轻度ILD,平均病程3.7(2.0)年。
  • 主要暴露为基线时任何CYC或MMF使用,主要比较一年后FVC,采用多变量线性回归。

主要发现

  • 暴露组一年后FVC较未暴露组高8.49%(95%CI:0.01-16.98%)。
  • 暴露组两年内无临床意义进展,未暴露组24.6%出现临床意义进展。

临床怎么用

  • 对于病程较短且FVC预测值>85%的SSc-ILD患者,可考虑早期使用CYC或MMF以保留肺功能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interstitial lung disease (ILD) is a leading cause of mortality in SSc. Little is known about the benefits of immunosuppressive drugs in mild ILD. Our aim was to determine whether use of CYC or MMF was associated with an improved ILD course in patients with normal or mildly impaired lung function. METHODS: A retrospective cohort of SSc subjects with ILD, disease duration below seven years and no exposure to CYC or MMF prior to the baseline visit was constructed from the Canadian Scleroderma Research Group registry. Subjects were categorized as having mild ILD if baseline forced vital capacity (FVC % predicted) was >85%. The primary exposure was any use of CYC or MMF at the baseline visit. FVC at one year was compared between exposed and unexposed subjects, using multivariate linear regression. RESULTS: Out of 294 eligible SSc-ILD subjects, 116 met criteria for mild ILD. In this subgroup, mean (s.d.) disease duration was 3.7 (2.0) years. Thirteen (11.2%) subjects were exposed to CYC or MMF at baseline. The one-year FVC was higher in exposed subjects compared with unexposed subjects, by a difference of 8.49% (95% CI: 0.01-16.98%). None of the exposed subjects experienced clinically meaningful progression over two years, whereas 24.6% of unexposed subjects did. CONCLUSION: In this real-world setting, CYC/MMF exposure at baseline was associated with higher FVC values and a lower risk of progression among subjects with mild ILD. These data suggest a window of opportunity to preserve lung function in SSc-ILD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Hoa S, Bernatsky S, Steele RJ, et al. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. Rheumatology (Oxford). 2020. PMID: 31535689. doi:10.1093/rheumatology/kez407

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。